Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (Nasdaq: TERN) announced equity inducement awards granted to two new employees effective November 1, 2025 under the 2022 Employment Inducement Award Plan.
The company granted options to purchase a total of 252,500 shares of common stock with a 10-year term and an exercise price of $8.26 per share (closing price on October 31, 2025). The options vest over four years, subject to continued service, and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN) ha annunciato premi di nomina azionaria concessi a due nuovi dipendenti con effetto 1 novembre 2025 ai sensi del piano di premi per l'assunzione del 2022.
L'azienda ha concesso opzioni per l'acquisto di un totale di 252.500 azioni ordinarie con una durata di 10 anni e un prezzo di esercizio di $8,26 per azione (prezzo di chiusura del 31 ottobre 2025). Le opzioni si maturano entro quattro anni, soggette a servizio continuato, e sono state approvate dal Compensation Committee in conformità alla Nasdaq Listing Rule 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN) anunció incentivos de acciones para dos nuevos empleados con efecto 1 de noviembre de 2025 bajo el Plan de Premios por Inducción de Empleo de 2022.
La compañía otorgó opciones para comprar un total de 252,500 acciones comunes con un plazo de 10 años y un precio de ejercicio de $8.26 por acción (precio de cierre el 31 de octubre de 2025). Las opciones vencen en cuatro años, sujetas a servicio continuo, y fueron aprobadas por el Comité de Compensación de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN)은 2명의 신규 직원에게 2022년 채용 유인 보상 계획에 따라 2025년 11월 1일자로 주식지급 유인 보상을 부여했다고 발표했습니다.
회사는 총 252,500주의 보통주를 매입할 수 있는 옵션을 10년 기한으로 부여했으며 행사가격은 주당 $8.26로, 이는 2025년 10월 31일 종가를 반영합니다. 이 옵션은 계속 근무한다는 조건 하에 4년에 걸쳐 vesting되며, 나스닥 상장 규칙 5635(c)(4)에 따라 보상위원회가 승인했습니다.
Terns Pharmaceuticals (Nasdaq : TERN) a annoncé des attributions d'intéressement en actions accordées à deux nouveaux employés à effet du 1er novembre 2025 dans le cadre du Plan d'attribution d'actions d'inductions de l'emploi 2022.
La société a accordé des options d'achat d'un total de 252 500 actions ordinaires avec une durée de 10 ans et un prix d'exercice de 8,26 $ par action (cours de clôture au 31 octobre 2025). Les options se vestent sur quatre ans, sous réserve de la poursuite du service, et ont été approuvées par le Comité de rémunération conformément à la règle de cotation Nasdaq 5635(c)(4).
Terms Pharmaceuticals (Nasdaq: TERN) hat zwei neuen Mitarbeitenden im Rahmen des Plan 2022 zur Beschäftigungsinduktion Aktienzuwendungen gewährt, mit Wirkung zum 1. November 2025.
Das Unternehmen gewährte Optionen zum Kauf insgesamt 252.500 Stammaktien mit einer Laufzeit von 10 Jahren und einem Ausübungspreis von 8,26 $ pro Aktie (Schlusskurs am 31. Oktober 2025). Die Optionen vesten über vier Jahre, vorbehaltlich fortgesetzter Dienste, und wurden vom Vergütungsausschuss gemäß der Nasdaq Listing Rule 5635(c)(4) genehmigt.
Terns Pharmaceuticals (Nasdaq: TERN) أعلنت منح مكافآت تحفيزية أسهمية لموظفين جديدين سرياناً من 1 نوفمبر 2025 بموجب خطة جوائز التوظيف للتحفيز لعام 2022.
منحت الشركة خيارات لشراء إجمالي 252,500 سهم من الأسهم العادية مع مدة عشر سنوات وسعر تنفيذ قدره $8.26 للسهم (سعر الإغلاق في 31 أكتوبر 2025). تصادق خيارات الاستحقاق على مدى أربع سنوات، رهناً باستمرار الخدمة، وموافقة عليها من قبل لجنة التعويض وفقًا لـ قاعدة إدراج ناسداك 5635(c)(4).
- None.
- None.
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.
The Company granted options to purchase 252,500 shares, in the aggregate, of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program, TERN-701, is a highly selective, oral, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for chronic myeloid leukemia. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Kaytee Bock
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
What did Terns (TERN) announce on November 4, 2025 about employee equity awards?
What is the exercise price and term of the Terns (TERN) inducement options granted November 1, 2025?
How do the Terns (TERN) options vest that were granted as inducements in November 2025?
Why were the Terns (TERN) equity awards approved under Nasdaq Listing Rule 5635(c)(4)?
How many shares did each new employee receive in Terns (TERN) inducement options on November 1, 2025?
